GENE ONLINE|News &
Opinion
Blog

Beta-thalassemia
Groundbreaking CRISPR/Cas9-based Genome Editing Therapy Secured the Second FDA Approval
2024-01-18
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
64th ASH Annual Meeting and Exposition: Discoveries That Reinvent Blood Disease Treatments
2022-12-20
Bluebird Bio’s Zynteglo Becomes First FDA-Approved Gene Therapy For Beta-Thalassemia
2022-08-18
CRISPR Biotech Editas Obtains FDA Rare Pediatric Disease Label
2022-04-27
FDA Grants Priority Review for bluebird bio’s β-Thalassemia Gene Therapy
2021-11-23
Vertex to Reap Majority Profits from Gene Editing Deal with CRISPR Therapeutics
2021-04-21
GeneOnline’s Top 10 Headlines of the Year
2020-12-30
CRISPR Gene-Edited Therapy CTX001 Raises Hopes for Sickle Cell Disease and β-Thalassemia Cures
2020-12-07
CRISPR/Cas9 Gene Editing in Cell and Gene Therapies
2020-11-08
CRISPR, Vertex’s Gene Editing Based Therapy, CTX001 Prospers in Hemoglobinopathy Trials
2020-06-18
Celgene, Acceleron’s novel anemia drug gets FDA green light for rare blood disorder
2019-11-11
LATEST
NVIDIA’s Global AI Strategy: A Multi-Region Push with Taiwan and Middle East as Key Hubs
2025-05-22
MIRDC Establishes CDMO Innovation Center in Boston to Advance into Innovative Healthcare
2025-05-22
A Look at Taiwan-German Collaborative Solutions in Precision Medicine, Drug Development, and Medical Tech
2025-05-21
ACOG Updates Pain Management Guidelines for IUD Insertions as Novavax Vaccine Gains Approval
2025-05-20
NIH Restores Research Funding to Previously Defunded Scientists Amid Policy Shifts
2025-05-20
Prime Medicine Reduces Workforce by 25 Percent and Appoints David Schenkein as New CEO
2025-05-20
UnitedHealth Group Stock Drops Amid Rising Medicare Advantage Costs and Regulatory Debates
2025-05-20
EVENT
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top